Limits...
Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy.

Convit J, Montesinos H, Oviedo H, Romero G, Maccarone B, Essenfeld E, Convit A, Palacios LE - Clin Transl Oncol (2015)

Bottom Line: Autologous tumor cell vaccines rely on the concept of preserving an individual's own tumorigenic makeup, expressing its unique set of tumor-associated antigens as well as antigenic elements from the surrounding stroma.Upon a 5-year follow-up, the survival rate was 60 % for the combined treatment.The data suggest that the combined treatment could be a feasible and safe therapeutic strategy.

View Article: PubMed Central - PubMed

Affiliation: Instituto de Biomedicina Dr. Jacinto Convit, Distrito Capital, Venezuela.

ABSTRACT

Introduction: Autologous tumor cell vaccines rely on the concept of preserving an individual's own tumorigenic makeup, expressing its unique set of tumor-associated antigens as well as antigenic elements from the surrounding stroma. These autologous tumor characteristics are usually presented with an immune adjuvant in the hopes of enhancing an immune response.

Methods: The autologous vaccine we used was composed of tumor cells combined with BCG and formalin. Animal safety and toxicity were evaluated using mice tumors for the immunotherapy. A small number of patients with advanced stage breast cancer were recruited for an uncontrolled study, using the vaccine solely or combined with chemotherapy/radiotherapy.

Results: The immunotherapy had shown to be safe in mice and humans. Upon a 5-year follow-up, the survival rate was 60 % for the combined treatment.

Conclusions: The data suggest that the combined treatment could be a feasible and safe therapeutic strategy. However, further controlled studies should be conducted.

No MeSH data available.


Related in: MedlinePlus

Estimated survival rates. The survival rate upon a 5-year period was plotted for the immunotherapy only (IT) group (inverted filled triangle) and the combined treated (CT/RT/IT) group (filled square), as well as for the overall survival across all subjects (filled circle). The calculated 5-year survival is indicated for each plot
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4608991&req=5

Fig1: Estimated survival rates. The survival rate upon a 5-year period was plotted for the immunotherapy only (IT) group (inverted filled triangle) and the combined treated (CT/RT/IT) group (filled square), as well as for the overall survival across all subjects (filled circle). The calculated 5-year survival is indicated for each plot

Mentions: Seeking to contrast standard treatment commonly used in patients with the immunotherapy proposed here, we calculated the estimated overall survival. For the immunotherapy-only group, the estimated survival was 83.3 %, while for the combined treatment (CT/RT/IT) was 50 %, resulting in an overall survival of 60 % across all subjects (Fig. 1). The high estimated survival obtained for the immunotherapy-only group might be due to the small number of subjects, as compared with the combined treated group. The calculated overall survival rate (60 %) and that for the combined treatment (50 %) are similar to the estimated survival reported by Parkin et al. [18] of 67 % for females with breast cancer in Latin America and the Caribbean. These results indicate that the immunotherapy proposed (solely or combined) was similarly effective to the standard treatment, and was considered safe and non-toxic. To reach a more significant conclusion on its effectiveness, a more specific analysis of the immunological effect involving a higher number of patients is necessary.Fig. 1


Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy.

Convit J, Montesinos H, Oviedo H, Romero G, Maccarone B, Essenfeld E, Convit A, Palacios LE - Clin Transl Oncol (2015)

Estimated survival rates. The survival rate upon a 5-year period was plotted for the immunotherapy only (IT) group (inverted filled triangle) and the combined treated (CT/RT/IT) group (filled square), as well as for the overall survival across all subjects (filled circle). The calculated 5-year survival is indicated for each plot
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4608991&req=5

Fig1: Estimated survival rates. The survival rate upon a 5-year period was plotted for the immunotherapy only (IT) group (inverted filled triangle) and the combined treated (CT/RT/IT) group (filled square), as well as for the overall survival across all subjects (filled circle). The calculated 5-year survival is indicated for each plot
Mentions: Seeking to contrast standard treatment commonly used in patients with the immunotherapy proposed here, we calculated the estimated overall survival. For the immunotherapy-only group, the estimated survival was 83.3 %, while for the combined treatment (CT/RT/IT) was 50 %, resulting in an overall survival of 60 % across all subjects (Fig. 1). The high estimated survival obtained for the immunotherapy-only group might be due to the small number of subjects, as compared with the combined treated group. The calculated overall survival rate (60 %) and that for the combined treatment (50 %) are similar to the estimated survival reported by Parkin et al. [18] of 67 % for females with breast cancer in Latin America and the Caribbean. These results indicate that the immunotherapy proposed (solely or combined) was similarly effective to the standard treatment, and was considered safe and non-toxic. To reach a more significant conclusion on its effectiveness, a more specific analysis of the immunological effect involving a higher number of patients is necessary.Fig. 1

Bottom Line: Autologous tumor cell vaccines rely on the concept of preserving an individual's own tumorigenic makeup, expressing its unique set of tumor-associated antigens as well as antigenic elements from the surrounding stroma.Upon a 5-year follow-up, the survival rate was 60 % for the combined treatment.The data suggest that the combined treatment could be a feasible and safe therapeutic strategy.

View Article: PubMed Central - PubMed

Affiliation: Instituto de Biomedicina Dr. Jacinto Convit, Distrito Capital, Venezuela.

ABSTRACT

Introduction: Autologous tumor cell vaccines rely on the concept of preserving an individual's own tumorigenic makeup, expressing its unique set of tumor-associated antigens as well as antigenic elements from the surrounding stroma. These autologous tumor characteristics are usually presented with an immune adjuvant in the hopes of enhancing an immune response.

Methods: The autologous vaccine we used was composed of tumor cells combined with BCG and formalin. Animal safety and toxicity were evaluated using mice tumors for the immunotherapy. A small number of patients with advanced stage breast cancer were recruited for an uncontrolled study, using the vaccine solely or combined with chemotherapy/radiotherapy.

Results: The immunotherapy had shown to be safe in mice and humans. Upon a 5-year follow-up, the survival rate was 60 % for the combined treatment.

Conclusions: The data suggest that the combined treatment could be a feasible and safe therapeutic strategy. However, further controlled studies should be conducted.

No MeSH data available.


Related in: MedlinePlus